Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis

PHASE4CompletedINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Acute Rhinosinusitis
Interventions
DRUG

Sinusitis Hevert SL Tablet

1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets

DRUG

Placebo for Sinusitis Hevert SL Tablet

1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets

Trial Locations (20)

Unknown

Immanuel Krankenhaus Berlin, Berlin

Site in Berlin, Berlin

Site in Bochum, Bochum

Site in Chemnitz, Chemnitz

Site in Köln, Cologne

Site in Dresden, Dresden

Site in Duisburg, Duisburg

Site in Düren, Düren

Site in Essen, Essen

Site in Frankfurt am Main, Frankfurt am Main

Site in Gars am Inn, Gars Am Inn

Site in Goch, Goch

Site in Haag, Haag

Site in Hamburg, Hamburg

Site in Heidelberg, Heidelberg

Site in Künzing, Künzing

Site in Leipzig, Leipzig

Site in Röthenbach, Röthenbach

Site in Wiesbaden, Wiesbaden

Site in Wolmirstedt, Wolmirstedt

All Listed Sponsors
lead

Hevert-Arzneimittel GmbH & Co. KG

INDUSTRY

NCT02296814 - Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis | Biotech Hunter | Biotech Hunter